Potential of liraglutide (Victoza) in multifactor treatment approach in type 2 diabetes mellitus

Pashkova E.Iu.

Rossiĭskiĭ universitet druzhby narodov, Moskva

Authors:

Pashkova E.Iu.

More about the authors

Journal: Problems of Endocrinology. 2012;58(2): 21‑24

Downloaded: 12

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Pashkova EIu. Potential of liraglutide (Victoza) in multifactor treatment approach in type 2 diabetes mellitus. Problems of Endocrinology. 2012;58(2):21‑24. (In Russ.)

Close metadata

To study the efficacy of treatment with liraglutide in women with type 2 DM and NAFLD. A group of 10 women with type 2 DM and obesity, with T2DM duration 6 months - 2 years, drug naïve or getting 1000-2500 gr metformin for at least 6 months with ultrasound markers of fatty liver and elevated ALT without hepatic insufficiency. Weight, BMI, HbA1C, ALT, AST, hepatic elasticity were measured before liraglutide 1.2 mg daily and 6 month after treatment. We got significant reduction of weight, BMI, HbA1C, in all treated women. In 7 women ALT level normalization was seen, in 3 women - ALT level reduction by 43, 37, 40% respectively. In 5 patients with initial fibrosis elasticity normalization was seen. In 1 - decrease of fibrosis degree and only in 1 - no improvement. Liraglutide in women with T2DM and NAFLD for 6 month helps to achieve weight, BMI, HbA1C reduction as well as elevated ALT normalization and hepatic fibrosis decrease.

Keywords:

diabetes mellitus

liraglutide

NAFLD

ALT

obesit

Authors:

Pashkova E.Iu.

Rossiĭskiĭ universitet druzhby narodov, Moskva

List of references:

Ford E.S. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005; 28:1769-1778.
Brunt E.M. Nonalcoholic steatohepatitis: pathologic features and differential diagnosis. Semin Diagn Pathol 2005; 22: 330-338.
Adams L.A., Angulo P., Lindor K.D. Nonalcoholic fatty liver Disease. Can Med Assoc J 2005; 172: 899-905.
Fabbrini E., Sullivan S., Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 2010; 51: 679-689.
Silverman J.E., Pories W.J., Caro J.E. Pathol. Ann 1989; 24: 275-302.
American Gastroenterological Association Medical Position Statement: Nonalcoholic Fatty Liver Disease. Gastroenterology 2002; 123: 1702-1704.
Verrijken A., Francque S., van Gaal L. The role of visceral adipose tissue in the pathogenesis of non-alcoholic fatty liver disease. Eur Endocrinol ; 7: 2: 96-103.
Root H.F. Protamine insulin in the treatment of diabetes mellitus. Trans Am Clin Climatol Ass 1936; 52: 40-51.
Hanley A.J., Williams K., Festa A. Elevation of markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2004; 53; 10: 2623-2632.
Bugianesi E., Gentilcore E. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in non-alcoholic fatty liver disease. Am J Gastroenterol 2005; 100; 5: 1082-1090.
Ratsiu V., Giral P. Rosiglitasone for nonalcoholic steatohepatitis: one year results of randomized placebo controlled Fatty Liver Improvement with Rosiglitasone (FLIRT) Trial. Gastroenterol 2008; 135: 1: 100-110.
Dedov I.I., Shestakova M.V. Sakharnyi diabet, rukovodstvo dlya vrachei. M 2003; 152-157.
Dedov I.I., Shestakova M.V. Inkretiny: novaya vekha v lechenii sakharnogo diabeta 2-go tipa. M 2010; 62-70.
Armstrong M.J. High Prevalence of Advanced NAFLD in Type 2 Diabetic Patients with Normal Liver Enzymes and Effect of Liraglutide on NAFLD: metaanalysis of the LEAD Program, 70th ADA Scientific Sessions Abstract Book, Poster number 1552, 2010.
Tushuin M.E., Bunck M.C. Incretinmimetics as a novel therapeutic option for hepatic steatosis. Liver Int 2006; 26: 8: 1015-1017.

Close metadata